Lupin signs license and supply agreement with Zentiva
The agreement is for commercialization of the company’s biosimilar Certolizumab Pegol
Lupin has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of the company’s biosimilar Certolizumab Pegol. The company will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise.
The company will undertake commercialization in the remaining regions, including USA and Canada.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
